Regencell Bioscience Holdings Limited Ordinary Shares (RGC) is a publicly traded Healthcare sector company. As of May 21, 2026, RGC trades at $27.39 with a market cap of $13.74B and a P/E ratio of 38.67. RGC moved +3.31% today. Year to date, RGC is +1.29%; over the trailing twelve months it is +131.52%. Its 52-week range spans $0.09 to $83.60. Rallies surfaces RGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns RGC stock?
Rallies tracks hedge fund and 13F ownership for RGC, including fund holders, share counts, and position changes when data is available.
BELL THOMAS D JR bought 25.00K (~$369.00K) on Aug 29, 2017.
KAPLAN STEPHEN A bought 10.00K (~$148.70K) on Aug 25, 2017.
Ownby David bought 7.50K (~$105.30K) on Aug 24, 2017.
RGC Analyst Consensus
RGC analyst coverage data. Average price target: $0.00.
Common questions about RGC
Who owns RGC stock?
Rallies tracks hedge fund and 13F ownership for RGC, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for RGC?
Yes. Rallies tracks hedge fund and 13F ownership data for RGC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RGC research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RGC. It does not provide personalized investment advice.
